WILMINGTON, Mass., Feb. 26 /PRNewswire/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its 2009 corporate highlights and year end financial results press release will be issued...
WILMINGTON, Mass., Feb. 2 PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ:DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its...
WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and...
Q3 Domestic PDT revenues up 32% year over year; Q3 Non-GAAP loss improves 86% year over year to ($0.2) million WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.®...
WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that global sales...
Second Consecutive Year DUSA Has Been Recognized WILMINGTON, Mass., Oct. 21 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R) (NASDAQ:DUSA), a specialty pharmaceutical company focused on...
WILMINGTON, Mass., Sept. 2 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA), a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and...
Q2 Domestic PDT revenues up 24% year over year; Kerastick margins reach a record high of 85% WILMINGTON, Mass., Aug. 11 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), a...
WILMINGTON, Mass., Aug. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA) announces that its corporate highlights and second quarter financial results press release will...
Amex to Trade Options on Nine Securities NEW YORK, March 8 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Tuesday, March 9, 2004, on the underlying...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.64 | 1.42857142857 | 44.8 | 45.78 | 44.49 | 44997 | 45.30019472 | SP |
4 | 3.15 | 7.44856940175 | 42.29 | 45.78 | 42.007782 | 55348 | 44.05074325 | SP |
12 | 1.27 | 2.87525469776 | 44.17 | 45.78 | 41.77 | 46955 | 43.88117218 | SP |
26 | 3.97 | 9.57318543525 | 41.47 | 45.78 | 37.5 | 32900 | 42.64480377 | SP |
52 | 8.91 | 24.3909115795 | 36.53 | 45.78 | 35.81 | 29816 | 41.27537386 | SP |
156 | 11.86 | 35.3186420488 | 33.58 | 45.78 | 24.67 | 26544 | 34.1386942 | SP |
260 | 12.72 | 38.8753056235 | 32.72 | 45.78 | 24.67 | 24383 | 34.26887988 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales